Tehran University of Medical Sciences
Office of Vice-Chancellor for Global Strategies & International Affairs
International Human Capacity Development (IHCD)
Code : 9345-331934      Publish Date : Tuesday, November 12, 2013 Visit : 46056

Intl. Congress form | International Congress Report | International Congress Report For Faculty | American Diabetes Associations 73rd Scientific Sessions

American Diabetes Associations 73rd Scientific Sessions
The Report of American Diabetes Associations 73rd Scientific Sessions by Dr.Azin Nowrouzi
Application Code :
306-0213-0030
 
Created Date : Thursday, October 03, 2013Update Date : Monday, November 11, 2013IP Address :194.225.51.101
Submit Date : Wednesday, November 06, 2013Email : anowrouzi@tums.ac.ir
Personal Information
Name : Azin
Surname : Nowrouzi
School/Research center : School of Medicine
Possition : Assistant professor
Tel : +98-21-64053318
E-mail : anowrouzi@tums.ac.ir
Information of Congress
Title of the Congress : American Diabetes Associations 73rd Scientific Sessions
Title of your Abstract : Cichorium Intybus L. (CI) Extract as an Insulin Sensitizer
Venue : McCormick Place, Chicago, IL
From : Friday, June 21, 2013
To : Tuesday, June 25, 2013
Abstract(Please copy/paste the abstract send to the congress) : Cichorium intybus L. seed extract (CI) was shown previously to improve glucose tolerance test (GTT) profile in a group of rats that were made mildly diabetic using a combination of Streptozotocin (STZ) and Niacinamide (NIA), called NIA/STZ group. The same effect was not observed in severe diabetic rats, STZ group (made diabetic using STZ alone) presumably due to the absence of insulin (INS) in this group of rats. The present study re-examined the effect of crude chicory seed extract on GTT in the presence and absence of INS. GTT was performed four times in a fasting group of rats (n=8) with severe diabetes. The test was performed in separate days by intraperitoneal administration of Glucose, Glucose + CI, Glucose + INS, or Glucose + CI + INS. The concentrations of Glucose and CI, which were dissolved in normal saline, were 2 g and 125 mg, per kg body weight, respectively; 5 U of regular INS was used for all the rats. Blood sugar was measured in blood from the tail by a glucometer every 30 minutes. The results showed that blood sugar decreased under the effect of INS, but CI significantly improved INS action in lowering blood sugar during two hours of GTT. The results suggest that the glucose lowering property of chicory depends on the presence of insulin; CI acts as an insulin sensitizer leading to alleviation of insulin resistance in target organs in type 2 diabetes mellitus.
Keywords of your Abstract : Insulin; Diabetes; Chicory; STZ; Niacinamide; Sensitizer
Acceptance Letter :
The presentation : Poster
The Cover of Abstract book :
Published abstract in the abstract book with the related code :
Where has your abstract been indexed? : ISI
If you choose other, please name :  
The Congress Reporting Form
How many volunteers were present at the Congress? : Many (perhaps a thousand or more)
Delegates from which countries presented in the congress? : All over the world
Were the delegates of any other organizations present in the congress? : Yes
If yes, please write the names of the organizations in the box : All universities and research organizations and clinical lab. and medical supply companies
What were the responses to your talking points? Were specific questions or concerns raised? : I had a poster presentation, not a talk. So far as I remember, I chose and preferred poster to oral at the time of submission, because I did not know what to expect. Next time, I will probably choose to present orally. In the presented work, we had used a raw extract of chicory seeds; many of those who saw and studied my poster, discussed the importance of identifying the active ingredients within the extract. This is an ongoing project that is still somewhat incomplete.
The important point is that no problem was detected or mentioned regarding the strategy and logic behind the data and conclusions.
If you met staff members, please list their full names & positions. : No
Please inform us if there are any follow up actions we need to talk with the members of the congress : I talked to many participants and professors. And I also visited several laboratories with diabetes-related activities, in Birmingham, Alabama. But may be due to their wrong judgment of Iran’s political stance and also because during the summer most professors were away, I was not very successful in collaborating with them.It is possible that if we present a better image of ourselves, the world would be pleased to work with us. I will contact you if such cooperation starts to happen. 
Yet, I would like to ask for software called "Graphpad Prism" available at www.graphpad.com. I would like this to be available for all of us.
I must remind you that since my sister is a nursing PhD student in Alabama, and I helped her with her Elisa measurements during my stay in the US. Although I do not expect anything in return to the assistance that I gave her, my name may be included among the authors of some of her papers and abstracts. If that happens, I will mention them in my future documents.
Your experiences about the travel processes(Providing ticket, accommodation,...) : Everything was good without major problems. Poster fee ($70.00) was different and not the same as registration fee ($465.00). And, at my request, a print copy of my poster was carried and placed on the board by the congress facilities (this service cost $125.00). Adding these together, the registration fee sums up to a total of $660.00.
Please give a briefing of your own observations and outcomes of the congress: : The congress was really large. Many oral and poster presentations were arranged. It was not possible to participate in all the orals due to their simultaneous timing, yet all the rooms were inside the same building and it was really easy to quickly go from one room to another. I got some feeling about what new research in diabetes tends to focus on, nowadays. I am thinking about adding a few new aspects and measurements to my current diabetes research to make the data more appealing to colleagues all over the world. It is important to keep in touch with the latest discoveries and leading-edge scientific thinking. 
There were medical supply companies with new drugs and insulin delivery equipments. One insulin delivery tool was not really an insulin pump, but an insulin storage device with a needle. The device could be fixed on the skin anywhere in the body, prefereably tummy, and the needle could be pushed into the skin. The device and the needle in it is supposed to stay there for 24 h and deliver basal insulin to the body; at the time of eating, a bolus of insulin is delivered by just a push of a small botton on the device, by the patient wearing it. The patient wearing this device can engage in any daily activity, even swimming. The device was called the "V GO".
A laboratory instrumentation was introduced by an American company that was interesting in that the future generations of this new device are going to be able to follow the changes that occur inside a whole tissue, like liver, after drug treatment without a need for homogenization and separation of cells and cytoplasm. Many things were new and interesting.